Endoplasmic reticulum stress targeted therapy for breast cancer

被引:39
作者
Xu, Di [1 ]
Liu, Zhen [1 ]
Liang, Ming-Xing [1 ]
Fei, Yin-Jiao [1 ]
Zhang, Wei [1 ]
Wu, Yang [2 ]
Tang, Jin-Hai [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Biobank, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Endoplasmic reticulum stress; Unfolded protein response; Signaling pathway; Anticancer drugs; UNFOLDED PROTEIN RESPONSE; OXIDOREDUCTASE ERO1-ALPHA DRIVES; ESTROGEN-RECEPTOR-ALPHA; ER STRESS; MESSENGER-RNA; CELL-DEATH; APOPTOSIS; ACTIVATION; INHIBITION; RESISTANCE;
D O I
10.1186/s12964-022-00964-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Recurrence, metastasis, and drug resistance are still big challenges in breast cancer therapy. Internal and external stresses have been proven to substantially facilitate breast cancer progression through molecular and systemic mechanisms. For example, endoplasmic reticulum stress (ERS) results in activation of the unfolded protein response (UPR), which are considered an important cellular stress response. More and more reports indicate its key role in protein homeostasis and other diverse functions involved in the process of breast cancer progression. Therefore, therapies targeting the activation of ERS and its downstream signaling pathways are potentially helpful and novel tools to counteract and fight breast cancer. However, recent advances in our understanding of ERS are focused on characterizing and modulating ERS between healthy and disease states, and so little attention has been paid to studying the role and clinical application of targeting ERS in a certain cancer. In this review, we summarize the function and main mechanisms of ERS in different molecular types of breast cancer, and focus on the development of agents targeting ERS to provide new treatment strategies for breast cancer.
引用
收藏
页数:12
相关论文
共 98 条
[1]   Kaempferol mitigates Endoplasmic Reticulum Stress Induced Cell Death by targeting caspase 3/7 [J].
Abdullah, Ahmad ;
Ravanan, Palaniyandi .
SCIENTIFIC REPORTS, 2018, 8
[2]   Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer [J].
Andruska, N. ;
Zheng, X. ;
Yang, X. ;
Helferich, W. G. ;
Shapiro, D. J. .
ONCOGENE, 2015, 34 (29) :3760-3769
[3]   Estrogen receptor a inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression [J].
Andruska, Neal D. ;
Zheng, Xiaobin ;
Yang, Xujuan ;
Mao, Chengjian ;
Cherian, Mathew M. ;
Mahapatra, Lily ;
Helferich, William G. ;
Shapiro, David J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (15) :4737-4742
[4]   A new strategy to ERADicate HER2-positive breast tumors? [J].
Arora, Sanjeevani ;
Golemis, Erica A. .
SCIENCE SIGNALING, 2015, 8 (378)
[5]   Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development [J].
Axten, Jeffrey M. ;
Romeril, Stuart P. ;
Shu, Arthur ;
Ralph, Jeffrey ;
Medina, Jesus R. ;
Feng, Yanhong ;
Li, William Hoi Hong ;
Grant, Seth W. ;
Heerding, Dirk A. ;
Minthorn, Elisabeth ;
Mencken, Thomas ;
Gaul, Nathan ;
Goetz, Aaron ;
Stanley, Thomas ;
Hassell, Annie M. ;
Gampe, Robert T. ;
Atkins, Charity ;
Kumar, Rakesh .
ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (10) :964-968
[6]   Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges [J].
Barua, David ;
Gupta, Ananya ;
Gupta, Sanjeev .
CANCER LETTERS, 2020, 486 :29-37
[7]   Immunotherapy in breast cancer: Current status and future directions [J].
Basu, Amrita ;
Ramamoorthi, Ganesan ;
Jia, Yongsheng ;
Faughn, Jon ;
Wiener, Doris ;
Awshah, Sabrina ;
Kodumudi, Krithika ;
Czerniecki, Brian J. .
IMMUNOTHERAPY OF CANCER, 2019, 143 :295-349
[8]   Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neupositive breast cancer cells [J].
Baumann, Jan ;
Wong, Jason ;
Sun, Yan ;
Conklin, Douglas S. .
BMC CANCER, 2016, 16
[9]   Treatment landscape of triple-negative breast cancer - expanded options, evolving needs [J].
Bianchini, Giampaolo ;
De Angelis, Carmine ;
Licata, Luca ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) :91-113
[10]   Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].
Bianchini, Giampaolo ;
Balko, Justin M. ;
Mayer, Ingrid A. ;
Sanders, Melinda E. ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690